The importance of inflammatory biomarkers in detecting and managing latent tuberculosis infection

被引:0
|
作者
Gunasekaran, Harinisri [1 ,2 ]
Ranganathan, Uma Devi [1 ,2 ,3 ]
Bethunaickan, Ramalingam [1 ,2 ,3 ]
机构
[1] ICMR Natl Inst Res TB, Dept Immunol, Chennai, India
[2] Univ Madras, Chennai, India
[3] Acad Sci & Innovat Res AcSIR, Fac Med Res, Ghaziabad, India
来源
FRONTIERS IN IMMUNOLOGY | 2025年 / 16卷
关键词
tuberculosis; biomarker; latent TB; inflammation; cytokine; chemokine; acute phase proteins; NECROSIS-FACTOR-ALPHA; ACUTE-PHASE RESPONSE; MYCOBACTERIUM-TUBERCULOSIS; T-CELLS; ACTIVE TUBERCULOSIS; IMMUNE-RESPONSE; TGF-BETA; PULMONARY TUBERCULOSIS; INTERFERON-GAMMA; INNATE IMMUNITY;
D O I
10.3389/fimmu.2025.1538127
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Infection with Mycobacterium tuberculosis (Mtb) triggers an autoimmune-like response in the host leading to further complications. One of the major concerns in eliminating Tuberculosis (TB) is identifying individuals with Latent Tuberculosis Infection (LTBI) who serve as major reservoirs of Mtb making them the important target group for TB eradication. Since no gold standard tests are available for detecting LTBI, the global burden of LTBI cannot be precisely determined. Since LTBI poses several challenges to worldwide healthcare, managing LTBI must be the key priority to achieve a TB-free status. The inflammatory mediators play a major role in determining the outcome of the Mtb infection and also their levels seem to change according to the disease severity. Identification of inflammatory mediators and utilizing them as diagnostic biomarkers for detecting the various stages of TB disease might help identify the reservoirs of Mtb infection even before they become symptomatic so that preventative treatment can be started early. In summary, this review primarily focuses on exploring different inflammatory markers along the course of the Mtb infection. Identifying LTBI-specific biomarkers helps to identify individuals who are at higher risk of developing TB and preparing them to adhere to preventive therapy thus minimizing the global burden of TB.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Treatment of Latent Tuberculosis Infection
    Patrick Tang
    James Johnston
    Current Treatment Options in Infectious Diseases, 2017, 9 (4) : 371 - 379
  • [42] Management of latent tuberculosis infection
    Brown, James
    THORAX, 2012, 67 (12) : 1121 - 1121
  • [43] Diagnosis of Latent Tuberculosis Infection
    Lardizabal, Alfred A.
    Reichman, Lee B.
    MICROBIOLOGY SPECTRUM, 2017, 5 (01):
  • [44] Latent Tuberculosis and HIV Infection
    Sara H. Bares
    Susan Swindells
    Current Infectious Disease Reports, 2020, 22
  • [45] Latent Tuberculosis Infection Care
    Gaskell, Katherine M.
    Pillay, Timesh D.
    Brown, James
    Belton, Moerida
    Mepham, Stephen O.
    Moore, David A. J.
    Lipman, Marc
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (10) : 1864 - 1864
  • [46] Latent Mycobacterium tuberculosis Infection
    Getahun, Haileyesus
    Matteelli, Alberto
    Chaisson, Richard E.
    Raviglione, Mario
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (22): : 2127 - 2135
  • [47] Etanercept and infection - latent tuberculosis
    Gonzalez-Sixto, B.
    Rodriguez-Prieto, M. A.
    ACTAS DERMO-SIFILIOGRAFICAS, 2010, 101 : 62 - 68
  • [48] Treatment of latent tuberculosis infection
    Meyer, BC
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (13): : 1293 - 1293
  • [49] Management of Latent Tuberculosis Infection
    Kim, Steven
    Thal, Rebecca
    Szkwarko, Daria
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 329 (05): : 421 - 422
  • [50] Treatment of latent tuberculosis infection
    Parekh, Madhavi J.
    Schluger, Neil W.
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2013, 7 (06) : 351 - 356